Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Interview: Cubist's Steven Gilman on succeeding with antibiotics

This article was originally published in Scrip

Executive Summary

It's no secret that we urgently need new antibiotics to combat the growing resistance to existing drugs. It's also no secret that commercial incentives to develop new antibiotics are lacking. Big pharma in particular has reduced its R&D in the space over recent years and that's understandable, given the scientific challenges, the limited patent life for medicines, the short duration of antibiotic treatment regimens, drug pricing constraints, regulatory uncertainties and the need to hold new antibiotics in reserve to delay the development of resistance for as long as possible.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts